-
Corporate Boards Are Not Leading Companies Where They Need To Go - By Tensie Whelan
Prof. Tensie Whelan op-ed: "Corporate Boards Are Not Leading Companies Where They Need To Go."
—— Opinion
-
Back To The Future: FASB To Reverse Goodwill Accounting - By Baruch Lev
Professor Baruch Lev op-ed: "Back To The Future: FASB To Reverse Goodwill Accounting"
—— Opinion
-
Robot Census: Gathering Data to Improve Policymaking on New Technologies - By Robert Seamans
Prof. Robert Seamans op-ed: "Robot Census: Gathering Data to Improve Policymaking on New Technologies"
—— Opinion
-
Will Biden Choose Paris Over Bismarck and Pierre? - By Paul Tice
Professor Paul Tice op-ed: "Will Biden Choose Paris Over Bismarck and Pierre?"
—— Opinion
-
Rethinking Antitrust - By Lawrence White
Prof Lawrence White op-ed: "Rethinking Antitrust"
—— Opinion
-
To Unite As A Nation, We Need To Begin With The Truth - By Michael Posner
Prof. Michael Posner op-ed: "To Unite As A Nation, We Need To Begin With The Truth"
—— Opinion
-
Boards Are Obstructing ESG — at Their Own Peril - By Tensie Whelan
Prof. Tensie Whelan op-ed: "Boards Are Obstructing ESG — at Their Own Peril."
—— Opinion
-
'Nationalize' Facebook and Twitter as Public Goods - By Vasant Dhar
Professor Vasant Dhar co-authored op-ed: “'Nationalize' Facebook and Twitter as Public Goods”
—— Opinion
-
The Rise, Fall, And Rise? Of The Conglomerates - By Baruch Lev
Professor Baruch Lev op-ed: "The Rise, Fall, And Rise? Of The Conglomerates"
—— Opinion
-
Amid A Threat To Democracy, How Companies Can Rebuild Trust - By Michael Posner
Prof. Michael Posner op-ed: "Amid A Threat To Democracy, How Companies Can Rebuild Trust"
—— Opinion
-
Is Employee Competition Helpful, or Harmful? - By Gavin Kilduff
Prof Gavin Kilduff research: "Is Employee Competition Helpful, or Harmful?"
—— Research Highlights
-
America Is the New Center of Global Instability - By Nouriel Roubini
Professor Nouriel Roubini op-ed: "America Is the New Center of Global Instability"
—— Opinion
-
A Fragile Recovery in 2021 - By Nouriel Roubini
Professor Nouriel Roubini op-ed: "A Fragile Recovery in 2021"
—— Opinion
-
What’s the Value of a Covid Cure? New Research from NYU Stern Professor Viral Acharya Finds an Answer
In the paper, titled, “The Value of a Cure: An Asset Pricing Perspective” the co-authors use stock market data and a vaccine progress indicator to calculate the value of a cure, i.e., the amount of wealth that someone would be willing to pay for obtaining a vaccine that puts an end to the ongoing pandemic, finding that a cure is worth 5-15% of total wealth.
—— Research Highlights
-
2020 Just the Start of a Testing Decade - By Nouriel Roubini
Professor Nouriel Roubini op-ed: "2020 Just the Start of a Testing Decade"
—— Opinion
